These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 15628403)

  • 21. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
    Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
    Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
    Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Niemann-Pick C disease: not your average lysosomal storage disease.
    Kaye EM
    Neurology; 2011 Jan; 76(4):316-7. PubMed ID: 21205672
    [No Abstract]   [Full Text] [Related]  

  • 24. Testing the mettle of PBT2 for Alzheimer's disease.
    Relkin NR
    Lancet Neurol; 2008 Sep; 7(9):762-3. PubMed ID: 18672401
    [No Abstract]   [Full Text] [Related]  

  • 25. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
    Portelius E; Zetterberg H; Andreasson U; Brinkmalm G; Andreasen N; Wallin A; Westman-Brinkmalm A; Blennow K
    Neurosci Lett; 2006 Dec; 409(3):215-9. PubMed ID: 17049739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primum non nocere.
    Kuhlmann D
    Arch Neurol; 2011 Mar; 68(3):397-8; author reply 398. PubMed ID: 21403031
    [No Abstract]   [Full Text] [Related]  

  • 27. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
    Motter R; Vigo-Pelfrey C; Kholodenko D; Barbour R; Johnson-Wood K; Galasko D; Chang L; Miller B; Clark C; Green R
    Ann Neurol; 1995 Oct; 38(4):643-8. PubMed ID: 7574461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cerebrospinal fluid levels of beta-amyloid protein 1-42 in Alzhemier disease].
    Yi YX; Jian ZJ
    Hunan Yi Ke Da Xue Xue Bao; 2002 Apr; 27(2):171-2. PubMed ID: 12575353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).
    Buerger K; Frisoni G; Uspenskaya O; Ewers M; Zetterberg H; Geroldi C; Binetti G; Johannsen P; Rossini PM; Wahlund LO; Vellas B; Blennow K; Hampel H
    Exp Gerontol; 2009 Sep; 44(9):579-85. PubMed ID: 19539742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
    Stuerenburg HJ; Ganzer S; Müller-Thomsen T
    Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
    J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers in Parkinson disease: It's time to combine.
    McKeown MJ; Peavy GM
    Neurology; 2015 Jun; 84(24):2392-3. PubMed ID: 25979702
    [No Abstract]   [Full Text] [Related]  

  • 33. Lumipulse G β-Amyloid Ratio Test for the Diagnosis of Alzheimer Disease.
    Lau K; Lin KW
    Am Fam Physician; 2023 May; 107(5):550-551. PubMed ID: 37192086
    [No Abstract]   [Full Text] [Related]  

  • 34. Beta-amyloid oligomer.
    Yu CW; Chen KT; Liu YL; Hsieh YC; Huang DW; Lee YF; Chien TJ; Hueng DY
    J Neurosurg; 2013 Nov; 119(5):1352. PubMed ID: 23952920
    [No Abstract]   [Full Text] [Related]  

  • 35. Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
    Donohue MC; Gamst AC; Aisen PS
    Alzheimers Dement; 2011 Mar; 7(2):245-6; author reply 247-9. PubMed ID: 21414558
    [No Abstract]   [Full Text] [Related]  

  • 36. Tapping into the biology of Alzheimer disease.
    Knopman DS
    Neurology; 2011 Feb; 76(6):496-7. PubMed ID: 21228299
    [No Abstract]   [Full Text] [Related]  

  • 37. Cerebrospinal Fluid from Alzheimer's disease patients promotes amyloid beta-protein oligomerization.
    Ikeda T; Ono K; Elashoff D; Condron MM; Noguchi-Shinohara M; Yoshita M; Teplow DB; Yamada M
    J Alzheimers Dis; 2010; 21(1):81-6. PubMed ID: 20413863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A screening UHPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species.
    Dillen L; Cools W; Vereyken L; Timmerman P
    Bioanalysis; 2011 Jan; 3(1):45-55. PubMed ID: 21175366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Amyloid beta peptide].
    Kowa H; Iwatsubo T
    Nihon Rinsho; 2004 Nov; 62 Suppl 11():307-9. PubMed ID: 15628403
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.